Sparks commentary

Healthcare

Sparks

Isofol (ST: ISOFOL) to receive financing to support Phase II & III trials of arfolitixorin in Japan
Published by Arron Aatkar, PhD

Isofol Medical has announced that Solasia Pharma, its development and commercialisation partner in Japan, intends to invest c SEK140m to support planned Phase II and III trials of arfolitixorin in the region, and the subsequent regulatory submission process for the candidate in metastatic colorectal cancer. According to Solasia, the Phase II trial is intended to take place across 2025 and 2026, followed by a Phase III trial and regulatory submission between 2027 and 2029. Isofol will support the programme and ensure alignment with the clinical development in other geographical regions.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.